CUDC-907: Phase I started

Curis began an open-label, dose-escalation, U.S. Phase I trial evaluating 30-180 mg oral CUDC-907 once daily in

Read the full 172 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE